Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

COVID-19

Blog

Atrys Health acquires the Swiss Radio-onkologie Amsler AG

February 24, 2021

24 February 2021.– Atrys Health (BME: ATRY), a Spanish company devoted to precision medical diagnosis and treatment services and a pioneer in the fields of telemedicine and cancer radiotherapy, announces the acquisition of 100% of Radio-onkologie Amsler AG (ROAG ), a Swiss company that offers advanced radiation oncology treatments. The transaction will be closed at the end of March.

Radio-onkologie Amsler, founded in 2003 by Dr. Med. Amsler, is the main private radiotherapy operator in the area of Basel. It offers radiotherapy treatments for cancer pathologies and has two medical centers that provide services to a reference population of 800,000, conducting more than 800 patients treatments a year.

In 2020 financial year, Radio-onkologie Amsler had a turnover of CHF 6.3 million (c. € 5.7 million euros) and no financial debt.

The acquired company has two TrueBeam Stx linear accelerators from Varian Medical Systems that suitable for advanced radiotherapy treatments, including SRT and SBRT, for a wide range of tumor types. Atrys will have now nine latest generation linear accelerators throughout Europe, distributed between Switzerland, Spain and Portugal.

In addition to expanding its range of state-of-the-art equipment, through this operation, Atrys reinforces its position in the field of radiotherapy in Europe and will be able to enhance Radio-onkologie Amsler current treatment portfolio with new high-precision radiotherapy services, pathology diagnosis, molecular and genetic diagnosis and medical oncology.

This acquisition responds to Atrys’ strategy to create a reference network of high-precision radiotherapy centers at a European level and provide the company with the critical mass necessary to centralize precision treatments planning and scale R&D on new hypofractionated radiotherapy treatments.

Santiago de Torres, Executive Chairman of Atrys, considers that “the acquisition represents a great step forward to consolidate Atrys as a leading company in advanced cancer treatment in Europe and confirms our growth strategy in the area. Furthermore, it allows us to enter in Switzerland, in the area of Basel, one of the main centers of activity for R&D applied to life sciences.”

Dr. Med. Amsler, CEO and founder of ROAG, who will continue to lead until the end of 2021 to ensure an orderly transition. Payment of the transaction will be made through a combination of payment in cash and payment in kind, through the issuance of 172,493 Atrys shares at a price of 9.05 euros per share.

Atrys has been advised in this corporate operation by Degroof Petercam Corporate Finance Team team and the E&Y team in Switzerland on legal and tax matters.

Dr. med. Beat Amsler has been advised on the transaction by Affentranger Associates on the M&A side and CMS von Erlach Poncet on the legal side.